HOME HELP CONTACT US FEEDBACK SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Rapid Responses: Submit a response Alert me when this article is cited Alert me when Rapid Responses are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Massoud, F. Search for Related Content PubMed Articles by Massoud, F.

Response

I thank Dr Lexchin for his interest in my paper published in the January issue of Canadian Family Physician.¹ He had some concerns about my conclusions’ not reflecting the evidence published in the recent literature on memantine.

First, my conclusion that memantine is "effective" should be interpreted in the clinical context of its use. This medication has been mostly studied in moderate to severe stages of Alzheimer disease (AD), where the natural history is inevitable deterioration of cognitive and functional capacities and behaviour. Therapeutic expectations need to be adapted accordingly. Most clinicians would agree that mild improvement, stabilization, and slower deterioration are all acceptable objectives at this stage of AD. Considering these objectives, published clinical trials with memantine do support its clinical superiority (alone or in combination with cholinesterase inhibitors) over placebo in the moderate to severe stages of AD.

Second, memantine’s pharmacoeconomic profile has not yet been adequately assessed, as clearly stated in my paper. The paper by Reisberg et al² showed a decrease in the time spent by caregivers supervising patients in the memantine group compared with the placebo group. How this translates in terms of cost savings and delay of institutionalization is unclear. Obviously, this issue is the most important consideration for funding organizations and is regularly evoked to justify not covering the medication.

	Footnotes

TOP Footnotes References

 
Competing interests

I have received grants or research support from and attended advisory board meetings for and received honoraria from the following companies: Janssen-Ortho, Lundbeck, Novartis, and Pfizer. I have received honoraria for CME events from the following companies: Janssen-Ortho, Lundbeck, and Novartis.

	References

TOP Footnotes References

 

1. Massoud F. Maladie d’Alzheimer. Mise à jour en 2007. Can Fam Physician 2007;53:50-4.[Abstract/Free Full Text]
2. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 2003;348:1333-41.[Abstract/Free Full Text]

This Article Full Text (PDF) Rapid Responses: Submit a response Alert me when this article is cited Alert me when Rapid Responses are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Massoud, F. Search for Related Content PubMed Articles by Massoud, F.